TY - JOUR
T1 - Usefulness of C-Reactive Protein and Interleukin-6 as Predictors of Outcomes in Patients With Chronic Obstructive Pulmonary Disease Receiving Pravastatin
AU - Lee, Tsung-Ming
AU - Lin, Mei S.
AU - Chang, Nen Chung
N1 - Funding Information:
This work was supported by Grants CMFHT 9501, CMFHR9502, CMFHR9503, and CM-TMU9601 from the Chi-Mei Medical Center, Tainan, Taiwan; and by Grant NSC 95-2314-B-384-009 from the National Science Council, Taiwan, Republic of China. Pravastatin was in part a generous gift from Sankyo Company, Ltd., Tokyo, Japan.
PY - 2008/2/15
Y1 - 2008/2/15
N2 - Inflammation is increased in chronic obstructive pulmonary disease (COPD) and plays a role in exercise intolerance. We investigated whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in high-sensitivity C-reactive protein (hs-CRP) over time are associated with corresponding changes in exercise capacity. In a randomized, double-blinded, and parallel design, 125 patients with clinically stable COPD were randomly assigned to receive placebo or pravastatin (40 mg/day) over a period of 6 months. Plasma hs-CRP levels were measured before randomization and during follow-up. Baseline characteristics were similar in the 2 groups. Exercise time remained stable throughout the study in the placebo group. Exercise time increased by 54% from 599 ± 323 seconds at baseline to 922 ± 328 seconds at the end (p
AB - Inflammation is increased in chronic obstructive pulmonary disease (COPD) and plays a role in exercise intolerance. We investigated whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in high-sensitivity C-reactive protein (hs-CRP) over time are associated with corresponding changes in exercise capacity. In a randomized, double-blinded, and parallel design, 125 patients with clinically stable COPD were randomly assigned to receive placebo or pravastatin (40 mg/day) over a period of 6 months. Plasma hs-CRP levels were measured before randomization and during follow-up. Baseline characteristics were similar in the 2 groups. Exercise time remained stable throughout the study in the placebo group. Exercise time increased by 54% from 599 ± 323 seconds at baseline to 922 ± 328 seconds at the end (p
UR - http://www.scopus.com/inward/record.url?scp=38849125493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38849125493&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2007.09.102
DO - 10.1016/j.amjcard.2007.09.102
M3 - Article
C2 - 18312772
AN - SCOPUS:38849125493
SN - 0002-9149
VL - 101
SP - 530
EP - 535
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 4
ER -